SCHEMBL30228494

SCHEMBL30228494

Cc1ccccc1-c1cc(=O)oc2cc(N(C)Cc3ccc(=O)[nH]c3)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGLV6-57 P01721 6/20 0.46
▸ KCNA3 P22001 3/20 0.44
▸ HSD17B3 P37058 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ACHE P22303 1/20 0.38
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31710568 0.87 IGLV6-57 (0.52) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30227891 0.80 IGLV6-57 (0.43) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228402 0.80 IGLV6-57 (0.46) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228077 0.79 KCNA3 (0.56) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228360 0.78 IGLV6-57 (0.47) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228207 0.78 IGLV6-57 (0.47) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228594 0.78 IGLV6-57 (0.45) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228039 0.78 IGLV6-57 (0.46) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228123 0.78 IGLV6-57 (0.51) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30227938 0.78 IGLV6-57 (0.51) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM IGLV6-57 4814/4885KCNA3 4258/4885HSD17B3 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback